Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins

GOTHENBURG, Sweden, Oct. 24, 2024 /PRNewswire/ -- 

Third quarter 

Sales of SEK 867 (848) million, an increase of 7% in local currencies and 2% in SEK.

Sales per region, in local currencies was +9% in EMEA, +2% in Americas and +9% in APAC.

Sales per business area, in local currencies was +13% in Consumables, +11% in Technologies and 0% in Genetics.

Gross margin increased to 58.6% (55.7).

Operating income before depreciation and amortisation (EBITDA) was SEK 289 (287) million, giving an EBITDA margin of 33.4% (33.9).

Operating cash flow decreased to SEK 206 million (214).

Net income was